**Products**  | Moray® micro forceps  
**Procedural Area**  | EUS  

| **Article**  | Technical feasibility, diagnostic yield, and safety of microforceps biopsies during EUS evaluation of pancreatic cystic lesions  
**Publication**  | Gastrointestinal Endoscopy (Online 2016); Video available  
**Author**  | Chetan Mittal, MD; Joshua C. Obuch, MD, MSc; Hazem Hammad, MD; Steven A. Edmundowicz, MD; Sachin Wani, MD; Raj J. Shah, MD; Brian C. Brauer, MD; Augustin R. Attwell, MD; Jeffrey B. Kaplan, MD; Mihir S. Wagh, MD.  
Denver, Colorado, USA  
**Purpose**  | To assess the technical feasibility, diagnostic yield, and safety of the Moray® micro forceps in pancreatic cystic lesions.  

- Microforceps biopsies were obtained in all 27 patients (100% tissue acquisition).  
- The microforceps biopsies provided a pathology diagnosis in 24 of 27 patients (88.9% diagnostic yield).  
- Subclassification diagnosis of cysts include:  
  - Mucinous Cyst – 9 patients  
  - Serous Cystadenoma – 4 patients  
  - Neuroendocrine Tumor – 1 patient  
  - Benign Cysts – 10 patients  
- Microbiopsy results drastically changed the diagnosis in 7 patients (26%), providing diagnoses (2 - mucinous cysts, 4 - serous cystadenoma, 1 – neuroendocrine tumor) otherwise not suggested by cytology or cyst fluid CEA.  

**Conclusions**  | Microforceps biopsies were associated with high technical success, and an excellent safety profile and may be a useful adjunctive tool, complementing existing EUS-FNA sampling protocols for PCL’s.